Skip to main content
. 2021 Mar 28;18(3):204–209. doi: 10.11909/j.issn.1671-5411.2021.03.011

Table 1. Baseline characteristics of the study patients.

All patients (n = 606) LDL-C levels
< 70 mg/dL (n =75) 70 to < 100 mg/dL ( n = 194) > 100 mg/dL (n = 337) P value
Data are presented as n (%) or median (IQR). AIS: acute ischaemic stroke; COPD: chronic obstructive pulmonary disease; GLU: glucose; HDL-C: high-density lipoprotein cholesterol; IQR: interquartile range; LDL-C: low-density lipoprotein cholesterol; mRS: modified Rankin Scale; TCH: total cholesterol; TG: triglycerides; TIA: transient ischaemic attack.
Age, yrs 58 (49−68) 62 (54−72) 59 (50−68) 57 (47−66) 0.01
Male 420 (69%) 52 (69%) 134 (69%) 234 (69%) 0.10
Prior mRS scores > 2 25 (4%) 8 (11%) 6 (3%) 11 (3%) 0.01
Medical history
 Hypertension 470 (78%) 55 (73%) 143 (74%) 272 (81%) 0.11
 Heart disease 95 (16%) 14 (19%) 26 (13%) 55 (16%) 0.50
 Diabetes mellitus 123 (20%) 28 (38%) 40 (21%) 55 (16%) < 0.01
 Previous AIS/TIA 96 (16%) 20 (27%) 36 (19%) 39 (12%) < 0.01
 Previous ICH 49 (8%) 10 (13%) 18 (9%) 21 (6%) 0.10
 COPD 13 (2%) 3 (4%) 3 (2%) 7 (2%) 0.46
 Alcohol consumption 225 (37%) 28 (37%) 59 (30%) 138 (41%) 0.05
Pre-medications
 Statin 60 (10%) 10 (13%) 23 (12%) 27 (8%) 0.21
 Antiplatelets 76 (13%) 14 (19%) 26 (13%) 36 (11%) 0.15
 Anticoagulants 6 (1%) 0 (0%) 1 (1%) 5 (1%) 0.36
 Anti-hypertensive 344 (57%) 45 (60%) 105 (54%) 194 (58%) 0.62
Laboratory data
 GLU, mg/dL 101 (88−126) 103 (94−146) 102 (87−123) 115 (88−126) 0.23
 TG, mg/dL 120 (89−168) 103 (80−142) 112 (83−157) 128 (96−192) < 0.01
 TCH, mg/dL 172 (146−198) 117 (105−132) 150 (139−163) 193 (177−218) < 0.01
 HDL-C, mg/dL 47 (39−56) 39 (31−51) 46 (37−55) 49 (42−58) < 0.01